Cannara Biotech Inc. has reported a significant earnings surprise, posting an EPS that exceeds expectations, marking a positive shift in its financial trajectory.
Recent earnings trend
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Cannara Biotech Inc.
LOVE.TO
LOVE.TO
Cannara Biotech Inc.
WealthAwesomeMarket cap
$176.82M
P/E
16.3x
52W high
$2.05
52W low
$1.55
1W change
+5.56%
Beta
0.35
Analyst Price Targets
Based on analyst covering LOVE
Wall Street analysts forecast LOVE stock price to rise 67.8% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.19
+67.8% Upside
Current Price
C$1.90
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on LOVE's historical volatility
30-Day Vol
40.1%
Annualized
90-Day Vol
35.0%
Annualized
Trend (90d)
+27.4%
Annualized drift
90d Mean
C$2.10
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$1.96 | C$1.71 โ C$2.25 |
| 60 trading days | C$2.03 | C$1.67 โ C$2.47 |
| 90 trading days | C$2.10 | C$1.65 โ C$2.66 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 1 analyst(s) cover this name; upcoming EPS consensus is available.
Beat estimates in 1 of the last 2 comparable quarter(s).
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-05-31 | 2026-07-15 | 0.0389 | 0.0300 | +29.7% |
| 2026-02-28 | 2026-04-14 | 0.0200 | 0.0400 | -50.0% |
| 2025-11-30 | 2025-11-30 | โ | 0.0100 | โ |
On July 15, 2026, Cannara Biotech Inc. (LOVE.TO) announced its fiscal Q3 2026 results, revealing an earnings per share (EPS) of 0.0389, surpassing analyst estimates of 0.03 by an impressive 29.67%. This marks a crucial milestone for the company as it continues to navigate the competitive cannabis market in Canada.
Investor takeaway: Cannara's recent earnings report indicates a promising financial outlook, with the company achieving profitability and demonstrating growth potential. Investors should consider the implications of this earnings surprise alongside the broader market trends in the cannabis sector.
EPS of 0.0389 vs. 0.03 Estimate
Cannara Biotech's EPS outperformance by 29.67% highlights its ability to exceed market expectations amid a challenging industry landscape.
Bull case
Cannara's strong earnings performance shows that the company is effectively managed and operating efficiently. They have also secured exclusive rights to innovative cannabis technology, which could enhance their product offerings and strengthen their position in the market.
Bear case
Despite the positive earnings surprise, Cannara's past performance has been inconsistent, including a previous earnings miss. Investors should stay cautious about the volatility that often comes with the cannabis sector.
Earnings Overview
โ
Financial Highlights
โ
Analyst Price Targets
โ
Wealth Awesome Price Forecast
โ
Advertisement
